Roles of Phosphorylation of N-Methyl-d-Aspartate Receptor in Chronic Pain

2022 ◽  
Author(s):  
Liangyu Pan ◽  
Tiansheng Li ◽  
Rui Wang ◽  
Weiheng Deng ◽  
Huangsheng Pu ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Aspartate Receptor

scholarly journals Ketamine for pain

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 1711 ◽  
Author(s):  
Kelly Jonkman ◽  
Albert Dahan ◽  
Tine van de Donk ◽  
Leon Aarts ◽  
Marieke Niesters ◽  
...  
Keyword(s):  
Emergency Department ◽  
Chronic Pain ◽  
Side Effects ◽  
Postoperative Pain ◽  
Cancer Pain ◽  
Literature Search ◽  
Analgesic Agent ◽  
Aspartate Receptor ◽  
Persistent Postoperative Pain ◽  
Meta Analyses

The efficacy of theN-methyl-D-aspartate receptor antagonist ketamine as an analgesic agent is still under debate, especially for indications such as chronic pain. To understand the efficacy of ketamine for relief of pain, we performed a literature search for relevant narrative and systematic reviews and meta-analyses. We retrieved 189 unique articles, of which 29 were deemed appropriate for use in this review. Ketamine treatment is most effective for relief of postoperative pain, causing reduced opioid consumption. In contrast, for most other indications (that is, acute pain in the emergency department, prevention of persistent postoperative pain, cancer pain, and chronic non-cancer pain), the efficacy of ketamine is limited. Ketamine’s lack of analgesic effect was associated with an increase in side effects, including schizotypical effects.

N-Methyl-D-Aspartate Receptor-Mediated Chronic Pain: New Approaches to Fibromyalgia Syndrome Etiology and Therapy

2007 ◽  
Vol 15 (2) ◽  
pp. 33-44 ◽  
Author(s):  
Samuel DeMaria ◽  
Afton L. Hassett ◽  
Leonard H. Sigal
Keyword(s):  
Chronic Pain ◽  
Fibromyalgia Syndrome ◽  
New Approaches ◽  
Aspartate Receptor

Chronic Pain: Levorphanol, Methadone, and theN-Methyl-d-Aspartate Receptor

2009 ◽  
Vol 12 (9) ◽  
pp. 765-766 ◽  
Author(s):  
Jack P. McNulty
Keyword(s):  
Chronic Pain ◽  
Aspartate Receptor

scholarly journals Nonselective and NR2B-selective N -methyl-d-aspartic Acid Receptor Antagonists Produce Antinociception and Long-term Relief of Allodynia in Acute and Neuropathic Pain

2011 ◽  
Vol 115 (1) ◽  
pp. 165-174 ◽  
Author(s):  
Maarten Swartjes ◽  
Aurora Morariu ◽  
Marieke Niesters ◽  
Leon Aarts ◽  
Albert Dahan
Keyword(s):  
Chronic Pain ◽  
Neuropathic Pain ◽  
Side Effects ◽  
Receptor Antagonist ◽  
Nerve Injury ◽  
Side Effect ◽  
Receptor Antagonists ◽  
Chronic Neuropathic Pain ◽  
Pain Model ◽  
Aspartate Receptor

Background At low dose, the nonselective N-methyl-D-aspartate receptor antagonist ketamine produces potent analgesia. In humans, psychedelic side effects limit its use. To assess whether other N-methyl-D-aspartate receptor antagonist have an improved therapeutic utility index, we compared antinociceptive, side effect, and locomotor activity of three N-methyl-D-aspartate receptor antagonists. Methods Ketamine, its active metabolite norketamine, and the NR2B-selective antagonist traxoprodil (CP-101,606) were tested in rat models of acute antinociception (paw-withdrawal response to heat) and chronic neuropathic pain (spared nerve injury). Side effects (stereotypical behavior, activity level) were scored and locomotor function of the nerve-injured paw was assessed using computerized gait analysis. In the chronic pain model, treatment was given 7 days after surgery, for 3 h on 5 consecutive days. Results All three N-methyl-D-aspartate receptor antagonists caused dose-dependent antinociception in the acute pain model and relief of mechanical and cold allodynia for 3-6 weeks after treatment in the chronic pain model (P < 0.05 vs. saline). In both tests, ketamine was most potent. Norketamine was as much as two times less potent and traxoprodil was up to 8 times less potent than ketamine (based on area under the curve measures). Nerve injury caused an inability to use the affected paw that either did not improve after treatment (ketamine, traxoprodil) or showed only a limited effect (norketamine). Traxoprodil, but not ketamine or norketamine, showed clear separation between effect and side effect. Conclusions The observation that traxoprodil causes relief of chronic pain outlasting the treatment period with no side effects makes it an attractive alternative to ketamine in the treatment of chronic neuropathic pain.

Too Much of a Good Thing? Treating the Emerging Syndrome of Opioid-Induced Hyperalgesia

2008 ◽  
Vol 21 (2) ◽  
pp. 165-168 ◽  
Author(s):  
Robert Leonard ◽  
Helen Kourlas
Keyword(s):  
Chronic Pain ◽  
Management Strategies ◽  
Treatment Strategies ◽  
Opioid Therapy ◽  
Medical Subject Headings ◽  
Opioid Rotation ◽  
Seek Health Care ◽  
Aspartate Receptor ◽  
Opioid Induced Hyperalgesia ◽  
Very High

Pain is the primary reason individuals seek health care, and chronic pain is the leading cause of disability. Patients with chronic pain often require treatment with strong analgesics, including opioids. Mounting evidence shows that very high opioid doses or rapidly escalating doses may lead to a paradoxical syndrome of increasing pain that is nonresponsive to opioid therapy. A review of the published literature describing the phenomenon of opioid-induced hyperalgesia was conducted, and management strategies were reviewed. A systematic search of PubMed using Medical Subject Headings terms to narrow search criteria identified 3 treatment strategies. The strategies evaluated in this literature review include opioid rotation, coadministration of N-methyl-D-aspartate receptor antagonists, and coadministration of opioid antagonists. Further research is needed to draw conclusive recommendations. As of now, the safest and most effective treatment strategy showing the best evidence involves the use of opioid rotation.

scholarly journals Targeting the N-Methyl-d-Aspartate Receptor for Chronic Pain Management

2000 ◽  
Vol 20 (5) ◽  
pp. 358-373 ◽  
Author(s):  
Kim Fisher ◽  
Terence J Coderre ◽  
Neil A Hagen
Keyword(s):  
Chronic Pain ◽  
Pain Management ◽  
Chronic Pain Management ◽  
Aspartate Receptor

scholarly journals Ketamine Use for Cancer and Chronic Pain Management

2021 ◽  
Vol 11 ◽  
Author(s):  
Clayton Culp ◽  
Hee Kee Kim ◽  
Salahadin Abdi
Keyword(s):  
Chronic Pain ◽  
Adverse Event ◽  
Case Reports ◽  
Aspartate Receptor ◽  
Opioid Induced Hyperalgesia ◽  
Central Nervous System Sensitization ◽  
The Central Nervous System ◽  
Resistant Depression ◽  
Human Use ◽  
Chronic Pain Conditions

Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative anesthetic and phencyclidine derivative. Due to an undesirable adverse event profile when used as an anesthetic it had widely fallen out of human use in favor of more modern agents. However, it has recently been explored for several other indications such as treatment resistant depression and chronic pain. Several recent studies and case reports compiled here show that ketamine is an effective analgesic in chronic pain conditions including cancer-related neuropathic pain. Of special interest is ketamine’s opioid sparing ability by counteracting the central nervous system sensitization seen in opioid induced hyperalgesia. Furthermore, at the sub-anesthetic concentrations used for analgesia ketamine’s safety and adverse event profiles are much improved. In this article, we review both the basic science and clinical evidence regarding ketamine’s utility in chronic pain conditions as well as potential adverse events.

Amitriptyline treatment of chronic pain in patients with temporomandibular disorders

2000 ◽  
Vol 27 (10) ◽  
pp. 834-841 ◽  
Author(s):  
O. Plesh ◽  
D. Curtis ◽  
J. Levine ◽  
W. D. Mccall Jr
Keyword(s):  
Chronic Pain ◽  
Temporomandibular Disorders

Dilemmas in the treatment of chronic pain

1996 ◽  
Vol 101 (1) ◽  
pp. S2-S5 ◽  
Author(s):  
B LISTER
Keyword(s):  
Chronic Pain
Sign in / Sign up

Export Citation Format

Share Document